Rowan-Virtua SOM and Durin Publish Findings of Blood Test for Detecting Alzheimer’s Disease

Rowan-Virtua SOM and Durin recently published findings of a new blood test for detecting Alzheimer’s disease. This new test is a major breakthrough in the fight against Alzheimer’s disease, as it can detect the disease in its early stages before symptoms even appear.

Alzheimer’s is a progressive neurodegenerative disorder that affects millions of people worldwide. It is characterized by a gradual decline in cognitive function, memory, and behavior. Currently, the only way to diagnose Alzheimer’s is through a series of cognitive tests and brain scans. Unfortunately, these tests are costly and time-consuming, and they often don’t detect the disease until it is too late.

The new blood test developed by Rowan-Virtua SOM and Durin is much more accurate and cost-effective than traditional methods. It works by detecting a specific protein in the blood called amyloid-beta. This protein is found in high levels in the brains of people with Alzheimer’s disease. By measuring the levels of amyloid-beta in the blood, doctors can determine whether or not a person has Alzheimer’s.

The new test is also much less invasive than traditional methods. It requires only a simple blood draw, and the results are available within days. This makes it much easier for doctors to diagnose Alzheimer’s disease in its early stages, when treatment is most effective.

The findings of this new blood test are a major breakthrough in the fight against Alzheimer’s disease. It provides an accurate, cost-effective, and non-invasive way to diagnose the disease in its early stages. This will allow doctors to provide better care for those affected by Alzheimer’s and give them a better chance at living a long and healthy life.

• SEO Powered Content & PR Distribution. Get Amplified Today.
• Platoblockchain. Web3 Metaverse Intelligence. Knowledge Amplified. Access Here.
• Source: Plato Data Intelligence: PlatoAiStream